Login to Your Account

Spin-off will take over protein drug development

HONG KONG – A Chinese protein drug developer received a $24 million investment to prepare a new subsidiary and pave the way for an initial public offering (IPO). Privately held Fortunerock (China) Ltd. is the parent company of Tianjin Sinobiotech Ltd., Sinobiotech (Tianjin) Ltd. and Beijing Bio-fortune Ltd. more »

Our Habitat for All Things Science
Promising compounds 'profoundly alter' disease course in SMA

Scientists from Roche Pharma Research and Early Development (pRED) and PTC Therapeutics Inc., with colleagues in academia, reported on small-molecule drugs that improved the symptoms of spinal muscular atrophy (SMA) by altering the splicing of the protein SMN2.

In mouse models of SMA, the compounds "profoundly altered the course of the disease," PTC Therapeutics CEO and co-author Stuart Peltz told BioWorld Today.



Partners in Focus